Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prenisolone · 1 trial · 1 indication
As measured by flow cytometry
As measured by flow cytometry
As measured by flow cytometry
As measured by flow cytometry
As measured by flow cytometry
As measured by blood concentration
As measured by flow cytometry
Assessed by central labortatory
As measured by the level of the hormone cortisol in the blood
As measured by the level of the hormone in the blood
As measured by blood concentration
As measured by blood concentration
As measured by blood concentration
As measured by blood concentration
As measured by urine concentration
As measured by urine concentration
As measured by urine concentration
As measured by urine concentration
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Specified dose on specified days |
| Arm B | PLACEBO_COMPARATOR | Specified dose on specified days |
| Name | Type | Description |
|---|---|---|
| Prenisolone | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on dose on specified days |
Inclusion Criteria: * Healthy male subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Body Mass Index (BMI) of 18 to 30 kilogram / square meter (kg/m2), inclusive * Signed informed consen...
Prenisolone is a small molecule being developed for immunoscience, an area of immunology research. It is currently in Phase 1 clinical development as an investigational drug. The drug is being studied for its pharmacodynamic effects in healthy subjects, with a focus on understanding its activity in the immune system.
Prenisolone is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this small molecule candidate for immunoscience applications. Bristol-Myers Squibb is responsible for the drug's development program, including its Phase 1 clinical trial.
Prenisolone is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical testing. The Phase 1 trial for Prenisolone has been completed, and the drug remains in early-stage development for immunoscience.
Prenisolone has one completed Phase 1 clinical trial registered under NCT03196557. The study, titled "A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject," enrolled 24 healthy male participants in the United States. The trial was placebo-controlled and assessed the drug's pharmacodynamic effects.
Prenisolone is also referred to as Prednisoline in clinical trial documentation. The Phase 1 study NCT03196557 uses the name Prednisoline in its title, while the drug is otherwise known as Prenisolone. Both names refer to the same investigational small molecule being developed by Bristol-Myers Squibb.